
Breaking News: Aileron Therapeutics Shares Exciting Results from Phase 1b Trial of LTI-03 for IPF Treatment
Positive Findings in Phase 1b Trial of High-dose LTI-03 for IPF Treatment Overview High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, has shown promising results in reducing expression of profibrotic proteins in both basal-like cells and fibroblasts, and improving lung function decline in patients with idiopathic pulmonary fibrosis (IPF). The Phase 1b clinical trial…